Shazia Farheen QURESHİ, Javed Ather SİDDİQUİ, Yousef Bin Ahmed SHAWOSH

Chlorpromazine-induced hyperprolactinemia in a young female and its relation with fibrocystic breast disease

We report the case of a 20 year old unmarried female patient who has been diagnosed as schizophrenia with intellectual disability. Patient was on chlorpromazine since last three years subsequently develop hyperprolactinemia, later manifested into fibrocystic breast disease. Hyperprolactinemia, is known for decades as neglected side effect of antipsychotic medication. Prolactin is secreted in a pulsatile manner by the anterior pituitary gland. The main physiological function of prolactin is to cause breast enlargement and galactorrhea initially and later develop to fibrocystic breast disease. Routine investigation also revealed hypothyroidism. Prolactin is known as immunomodulator, and has been linked to benign or malignant tumor growth.

PDF

___

1. Meltzer HY, Fang VS. The effect of neuroleptics serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976;33:279-86.
2. David SR, Taylor CC, Kinon BJ, Breier A. The effect of olanzapine, resperidone, and haloperidol on plasma prolactin levels in patient with schizophrenia. Clin Ther. 2000;22:1085-96.
3. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia mechanisms, clinical features, and management. Drugs. 2004;64:2291-314.
4. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotictreated patients. CNS Drugs. 1998:10:209-22.
5. Smith S. Effect of antipsychotics on sexual and endocrine functions in women. Implication for clinical practice. J Clin Psychopharmacol 2003;23:S27-S32.
6. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull. 1996;22:447-54.
7. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003;182;199-204.
8. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamicpituitary-gonadal axis. J Clin Psychopharmacol. 2002;22:109-14.
9. Halbreich U, Shen J, Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am J Psychiatry. 1996;153:559-60.
10. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. Dopamine antagonists and development of breast cancer. Arch Gen Psychiatry. 2002;59:1147-54.
11. Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans; breast and prostate cancer. J Psychopharmacol. 2008;22:20-7.
12. Bolyakov A. Paduch DA. Prolactin in man`s health and disease. Curr Opin Urol. 2011;21:527-34.
13. Wode-Helgodt B, Eneroth P, Fyrö B, Gullberg B, Sedvall G. Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatr Scand. 1977;56:280-93.
14. Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am. 1988;17:213-23.
15. Bromocriptine mesylate [database on the Internet]. Facts & Comparison eAnswers [online]. Wolters Kluwer Health, Inc; 2011. [Accessed March 10, 2011]
16. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12-9.